Adjuvant Trastuzumab

Patients with HER2-positive, node-negative breast tumors 1-2 cm should generally receive adjuvant trastuzumab/ chemotherapy as part of their treatment.

Patients with HER2-positive, node-negative breast tumors smaller than 1 cm should generally receive adjuvant trastuzumab/
chemotherapy as part of their treatment.

When using adjuvant trastuzumab for patients with breast cancer, which adjuvant chemotherapy regimen do you generally use?

When using adjuvant trastuzumab for patients with breast cancer, which adjuvant chemotherapy regimen do you generally use?

Trastuzumab monotherapy is a reasonable nonprotocol adjuvant treatment option for patients with breast cancer who are unable to receive chemotherapy.

Trastuzumab monotherapy is a reasonable nonprotocol adjuvant treatment option for patients with breast cancer who are unable to receive chemotherapy.

Approximately what percent of your patients on adjuvant trastuzumab fail to complete one year of trastuzumab therapy?

Have you used TCH as nonprotocol adjuvant therapy for patients with HER2-positive tumors?

For a woman in average health with a 1.2-cm, Grade II, ER-positive/PR-positive, HER2-positive tumor with 3 positive nodes, how would you compare TCH to your preferred anthracycline/ taxane/ trastuzumab regimen?

For a woman in average health with a 1.2-cm, Grade II, ER-positive/PR-positive, HER2-positive tumor with 3 positive nodes, how would you compare TCH to your preferred anthracycline/ taxane/ trastuzumab regimen?

How would you feel in general about recommending participation in a randomized trial of TCH alone or with bevacizumab in women with HER2-positive breast cancer?

Are you aware of the new data from the BCIRG 006 study comparing AC

TH and to TCH in the adjuvant treatment of HER2-positive, early breast cancer presented at the 2006 San Antonio Breast Cancer Symposium?

If yes, please respond to the following statements about the BCIRG 006 study: THC and AC

TH had roughly equivalent efficacy, and each was superior to AC

If yes, please respond to the following statements about the BCIRG 006 study: TCH had lower cardiovascular toxicity compared to AC

If yes, please respond to the following statements about the BCIRG 006 study: The TOPO II test is useful to determine whether an anthracycline should be usedin the HER2-positive setting

Have you ever ordered a TOPO II test?

Would you be comfortable enrolling a patient with a 1.2-cm, HER2-positive, ER-negative, node-negative tumor in a randomized clinical trial that has one arm containing lapatinib as the only anti-HER2 therapy?

Would you be comfortable enrolling a patient with a 1.2-cm, HER2-positive, ER-negative tumor with 3 positive nodes in a randomized clinical trial that has one arm containing lapatinib as the only anti-HER2 therapy?